| Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years. | |
| | |
MedLine Citation:
|
PMID: 18721704 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To determine differences in endophthalmitis rates with prophylactic use of third- versus fourth-generation fluoroquinolones in cataract surgery. SETTING: University hospitals. METHODS: This retrospective cross-sectional (prevalence) study looked at patients who had phacoemulsification at a university eye center over a 10-year period. A nosocomial infectious reporting database was used to report endophthalmitis occurrences. The following were performed: a retrospective analysis of prospectively collected data to establish endophthalmitis rates, a prevalence analysis of the postoperative quinolone antibiotic prescribed, and a comparative analysis of endophthalmitis rate versus postoperative quinolone prescribed for all reported endophthalmitis cases. The main outcome measure was occurrence of endophthalmitis after cataract surgery. RESULTS: From January 1997 to December 2007, 29276 patients had phacoemulsification cataract surgery. Forty cases of postoperative bacterial endophthalmitis were reported. The endophthalmitis rate from January 1997 to August 2003 associated with use of third-generation fluoroquinolones (ciprofloxacin, ofloxacin) was 0.197% (33/16710). The rate from September 2003 to December 2007 associated with fourth-generation fluoroquinolones (gatifloxacin, moxifloxacin) was 0.056% (7/12566). The difference between third- and fourth-generation drugs was statistically significant (P = .0011). Of fourth-generation fluoroquinolone infections, 0.015% (1/6651) and 0.1% (6/5915) were associated with gatifloxacin and moxifloxacin, respectively. The difference between drugs was statistically significant (P = .040). CONCLUSIONS: The differences in the pharmacokinetic and pharmacodynamic properties of quinolone antibiotics may affect the endophthalmitis incidence after cataract surgery. The significant difference in endophthalmitis rates between gatifloxacin and moxifloxacin requires further study. |
| | |
Authors:
|
Michael K Jensen; Richard G Fiscella; Majid Moshirfar; Barbara Mooney |
Related Documents
:
|
17457184 - Treatment of progressive keratoconus by riboflavin-uva-induced cross-linking of corneal... 18320514 - Cataract surgery in exudative uveitis: effectiveness of total lens removal, anterior vi... 15097124 - A comparative evaluation of the efficacy of intraoperative mitomycin c use after the ex... 12747534 - Effect of photorefractive keratectomy and laser in situ keratomileusis in high myopia o... 23228404 - A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autolog... 10327494 - Medical therapy of bone and joint tuberculosis in 1998. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Journal of cataract and refractive surgery Volume: 34 ISSN: 0886-3350 ISO Abbreviation: J Cataract Refract Surg Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-08-25 Completed Date: 2008-10-03 Revised Date: 2013-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 8604171 Medline TA: J Cataract Refract Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 1460-7 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Services, Moran Eye Center, University of Utah Hospital, 65 North Medical Drive, Salt Lake City, UT 84132, USA. mike.jensen@hsc.utah.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Anti-Infective Agents / therapeutic use* Antibiotic Prophylaxis* Aza Compounds / therapeutic use Ciprofloxacin / therapeutic use Cross-Sectional Studies Endophthalmitis / epidemiology*, prevention & control Eye Infections, Bacterial / epidemiology*, prevention & control Female Fluoroquinolones / therapeutic use Humans Male Middle Aged Ofloxacin / therapeutic use Phacoemulsification* Postoperative Complications* Prevalence Quinolines / therapeutic use Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Infective Agents; 0/Aza Compounds; 0/Fluoroquinolones; 0/Quinolines; 82419-36-1/Ofloxacin; 85721-33-1/Ciprofloxacin; L4618BD7KJ/gatifloxacin; U188XYD42P/moxifloxacin |
| Comments/Corrections | |
Comment In:
|
J Cataract Refract Surg. 2009 Feb;35(2):206; author reply 207-9
[PMID:
19185216
]
J Cataract Refract Surg. 2009 Feb;35(2):206-7; author reply 207-9 [PMID: 19185215 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Next Document: Microincision multifocal intraocular lens with and without a capsular tension ring: optical quality ...